According to the Zhitong Finance App, Dongyang Pharmaceutical (06887) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 1,075 million yuan and gross profit of 578 million yuan. The company's equity shareholders should have accounted for a loss of 604 million yuan, with a loss of 1.09 yuan per share.
The company plans to invest strong operating cash flow in R&D activities to greatly improve the efficiency of capital use and provide sufficient support for the R&D pipeline. Relying on financial advantages, the company will continue to strengthen its independent research and development platform, strive to provide patients with better medical solutions and affordable pharmaceutical products, and focus on arranging drugs with huge market potential in the field of indications. Strong R&D capabilities will continuously enrich future commercial products and lay a solid foundation for sustainable business growth and long-term value creation.
The company will streamline the decision-making process, improve the efficiency of business decision-making, respond to market changes and various challenges as soon as possible, flexibly adjust various pharmaceutical sales channels, and promote the dual global layout of the market and technology. At the same time, the company will accelerate the integration of the back-office architecture and promote an intelligent back-office system that integrates all processes, including finance, R&D, sales, procurement, inventory, administrative office systems and digital infrastructure. In addition, the company will optimize and adjust previous related transaction arrangements to improve decision-making and capital allocation efficiency and reduce governance costs.